Technical Analysis for CPRX - Catalyst Pharmaceutical Partners, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Historical CPRX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Walk | Strength | -1.59% | |
| Outside Day | Range Expansion | -1.59% | |
| Overbought Stochastic | Strength | -1.59% | |
| Upper Bollinger Band Touch | Strength | -1.59% | |
| Stochastic Sell Signal | Bearish | -2.76% | |
| Upper Bollinger Band Walk | Strength | -2.76% | |
| Overbought Stochastic | Strength | -2.76% | |
| Up 3 Days in a Row | Strength | -2.76% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/16/2020
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. It focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. The company's principal product includes Firdapse that is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. It also develops CPP-115, a GABA aminotransferase inhibitor for the treatment of epilepsy and other selected central nervous disease indications; and CPP-109 for the treatment of Tourette Syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.
Health Pharmaceutical Pharmaceutical Industry Medication Disorders Virotherapy Health Sciences Epilepsy Pharmaceutical Sciences Biomarin Pharmaceutical Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Novato Tourette Syndrome Treatment Of Epilepsy
Health Pharmaceutical Pharmaceutical Industry Medication Disorders Virotherapy Health Sciences Epilepsy Pharmaceutical Sciences Biomarin Pharmaceutical Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Novato Tourette Syndrome Treatment Of Epilepsy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.67 |
| 52 Week Low | 2.55 |
| Average Volume | 1,777,098 |
| 200-Day Moving Average | 4.46 |
| 50-Day Moving Average | 4.60 |
| 20-Day Moving Average | 4.68 |
| 10-Day Moving Average | 4.83 |
| Average True Range | 0.23 |
| ADX | 14.76 |
| +DI | 21.96 |
| -DI | 13.27 |
| Chandelier Exit (Long, 3 ATRs ) | 4.49 |
| Chandelier Exit (Short, 3 ATRs ) | 4.70 |
| Upper Bollinger Band | 5.17 |
| Lower Bollinger Band | 4.20 |
| Percent B (%b) | 0.76 |
| BandWidth | 20.69 |
| MACD Line | 0.13 |
| MACD Signal Line | 0.10 |
| MACD Histogram | 0.0375 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.24 | ||||
| Resistance 3 (R3) | 5.26 | 5.19 | 5.19 | ||
| Resistance 2 (R2) | 5.19 | 5.12 | 5.18 | 5.17 | |
| Resistance 1 (R1) | 5.07 | 5.07 | 5.03 | 5.04 | 5.15 |
| Pivot Point | 4.99 | 4.99 | 4.98 | 4.98 | 4.99 |
| Support 1 (S1) | 4.87 | 4.92 | 4.83 | 4.84 | 4.73 |
| Support 2 (S2) | 4.80 | 4.87 | 4.78 | 4.71 | |
| Support 3 (S3) | 4.67 | 4.80 | 4.69 | ||
| Support 4 (S4) | 4.64 |
